LIGAND PHARMACEUTICALS INCORPORATED (LGND) Operating margin 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) operating margin by fiscal year — reported operating income divided by reported revenue.
15.3%FY2025 · since FY2016: 40.3% → 15.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 15.3% | +28.8 pp |
| FY2024 | -13.5% | -22.6 pp |
| FY2023 | 9.1% | +7.5 pp |
| FY2022 | 1.5% | -41.4 pp |
| FY2021 | 43.0% | +20.1 pp |
| FY2020 | 22.9% | -648.1 pp |
| FY2019 | 671.0% | +605.9 pp |
| FY2018 | 65.1% | +16.9 pp |
| FY2017 | 48.2% | +8.0 pp |
| FY2016 | 40.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →